NCCN to Host 9th Annual Congress: Hematologic Malignancies™ in New York, NY
The National Comprehensive Cancer Network® (NCCN®) will host its 9th Annual Congress: Hematologic Malignancies™ in New York, NY, September 19 – 20, 2014.
Source Newsroom: National Comprehensive Cancer Network® (NCCN®)
Newswise — FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) will host its 9th Annual Congress: Hematologic Malignancies™ at the New York Marriott Marquis, in New York, NY, September 19 – 20, 2014.
Moderated by Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center, chair of the NCCN Guidelines Panel for Non-Hodgkin's Lymphomas, this year's congress will focus on the new approaches to patient management and updates that have been incorporated into the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for hematologic malignancies and associated supportive care regimens. Nearly 700 oncology professionals are expected to attend the event, including expert speakers representing the NCCN Member Institutions.
“With more than 15 presentations and live debates, this day-and-a-half event provides participants with the latest evidence-based advancements and choices in the treatment of patients with hematologic malignancies,” said Robert W. Carlson, MD, Chief Executive Officer, NCCN. “NCCN thanks the esteemed expert panel members, representing top cancer institutions throughout the country, for partaking in this annual event.”
The 2014 Annual Congress agenda includes presentations about the latest developments in the care of patients with hematologic malignancies, such as molecular monitoring, targeted therapies, and molecular prognostication. In addition, attendees will have the opportunity to attend two live debates: “Is There a Role for Upfront Transplant in the Current Management of Symptomatic Multiple Myeloma?” featuring Kenneth C. Anderson, MD, Dana-Farber/Brigham and Women’s Cancer Center, and Sergio A. Giralt, MD, Memorial Sloan Kettering Cancer Center; and “Follicular Lymphoma and the Role of Maintenance Therapy,” featuring Richard I. Fisher, MD, Fox Chase Cancer Center, and Dr. Zelenetz.
Saturday’s agenda also includes a Satellite Symposium: “Recent Developments in Treating Indolent Non-Hodgkin’s Lymphomas,” featuring Steven H. Horwitz, Memorial Sloan Kettering Cancer Center, and Dr. Zelenetz.
The event’s full agenda is available at NCCN.org/HEM.
This congress is approved for AMA PRA Category 1 Credit(s)™ for physicians and is also accredited for case managers, nurses, pharmacists, and other health care professionals.
To learn more about the NCCN 9th Annual Congress: Hematologic Malignancies™, or to register, visit NCCN.org/HEM.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 25 of the world’s leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.
The NCCN Member Institutions are: Fred and Pamela Buffett Cancer Center at The Nebraska Medical Center, Omaha, NE; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.